<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE html
  PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"><head xmlns:reg="http://www.gov.bc.ca/2013/legislation/regulation" xmlns:bcl="http://www.gov.bc.ca/2013/bclegislation" xmlns:in="http://www.qp.gov.bc.ca/2013/inline" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:xs="http://www.w3.org/2001/XMLSchema"><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><META content="text/html; charset=utf-8" http-equiv="Content-Type"></META><META http-equiv="X-UA-Compatible" content="IE=edge"></META><title>Drug Price Regulation</title><link href="/standards/REGS-CSS.css" rel="stylesheet" type="text/css" /><script src="https://code.jquery.com/jquery-1.7.1.min.js" type="text/javascript"></script><script src="/standards/hitNav.js" type="text/javascript"></script><script type="text/javascript">							function launchNewWindow(url)
							{
								window.open(url,'','toolbar=1,scrollbars=1,location=0,statusbar=1,menubar=1,resizable=1,');
							}
							window.onload = function() {
								document.body.style.display = "block";
							}
						</script><script type="text/javascript">
							function showhide(elem) {
							var div = elem.nextSibling;
							while (div.nodeType!=1) {
							div = div.nextSibling;
							}
							if (div.style.display == 'block') {
							div.style.display = 'none';
							} else {
							div.style.display = 'block';
							}	
							}
						</script><style type="text/css">
							span.container {
							position: relative;
							}
							span.box {
							display: none;
							}
							a:hover+span.box, span.box iframe:hover, span.box:hover {
							display: block;
							z-index: 100;
							position: absolute;
							left: 10px;
							}
							#toolBar {
							position:fixed;
							top:5px;
							left:0;
							width: 100%;
							height: 25px;
							padding: 5px 10px;
							border-bottom: 3px solid #333; /* some styling */
							}
						</style><style type="text/css" media="print">
							#contentsscroll{
							height: auto;
							overflow-y: auto;
							}
							#toolBar{
							display: none; 
							}
						</style><style type="text/css" media="screen">
							#contentsscroll{
							height: 90%;
							width: 98%;
							padding-left: 20px;
							margin-top: 40px;
							overflow: auto;
							}
							
							body {
							display: none;
							}
						</style></head><body xmlns:reg="http://www.gov.bc.ca/2013/legislation/regulation" xmlns:bcl="http://www.gov.bc.ca/2013/bclegislation" xmlns:in="http://www.qp.gov.bc.ca/2013/inline" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:xs="http://www.w3.org/2001/XMLSchema" bgcolor="#FFFFFF" text="#000000"><div xmlns="" id="toolBar"><a id="searchHit" href="#">Search Results</a> | <a id="clearSearch" href="#">Clear Search</a> | <a id="prevHit" href="#">Previous (in doc)</a> | <a id="nextHit" href="#">Next (in doc)</a> | <a id="pdocHit" href="#">Prev Doc</a> | <a id="ndocHit" href="#">Next Doc</a></div><div id="contentsscroll"><div id="header"><table border="0" cellpadding="4" cellspacing="0" width="100%"><tr><td class="sizesmall" valign="bottom">Copyright © King's Printer,<br />						Victoria, British Columbia, Canada</td><td align="right" class="sizemedium"><a href="/standards/Licence.html"><strong>Licence</strong></a><br /><a href="/standards/Disclaimer.html" target="_blank"><strong>Disclaimer</strong></a></td></tr></table></div><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="sizetext1" valign="top">B.C. Reg. 344/2012<br /><span class="sizetext2">O.C. 783/2012</span></td><td align="right" class="sizetext1" valign="top">Deposited November 23, 2012<br /><span class="sizetext2">effective sections 1 to 3, 6, 7 and 17 March 1, 2013<br /> remainder effective April 1, 2013</span></td></tr></tbody></table><span class="regCurrency"><strong>This consolidation is current to March 5, 2024.</strong></span><h5 align="center"><strong><a href="/civix/content/crbc/crbc/1922970521/370494221/344_2012_dir/?xsl=/templates/browse.xsl">Link to consolidated regulation (PDF)</a></strong></h5><h5 align="center"><strong><a href="/civix/document/id/complete/statreg/344_2012_pit">Link to Point in Time</a></strong></h5><div id="actname"><h2>Pharmaceutical Services Act</h2></div><div id="title"><h2>Drug Price Regulation</h2></div><p align="center">[includes amendments up to B.C. Reg. 22/2019, April 1, 2019]</p><p align="center"></p><div id="contents"><table border="0" cellpadding="3" cellspacing="0"><tr><th colspan="3"><em>Contents</em></th></tr><tr><td align="left" class="part" colspan="3" valign="top"><a href="#part1">Part 1 — Definitions and Application</a></td></tr><tr><td align="left"> </td><td align="right" valign="top" width="auto"><a href="#section1">1</a></td><td align="left" valign="top"><a href="#section1">Definitions</a></td></tr><tr><td align="left"> </td><td align="right" valign="top" width="auto"><a href="#section2">2</a></td><td align="left" valign="top"><a href="#section2">Application</a></td></tr><tr><td align="left" class="part" colspan="3" valign="top"><a href="#part2">Part 2 — Maximum Amounts Payable by Minister</a></td></tr><tr><td align="left"> </td><td align="left" class="division" colspan="2" valign="top"><a href="#division_d2e351">Division 1 — Drug Programs</a></td><tr><td align="left"> </td><td align="right" valign="top" width="auto"><a href="#section3">3</a></td><td align="left" valign="top"><a href="#section3">Low cost alternative program</a></td></tr><tr><td align="left"> </td><td align="right" valign="top" width="auto"><a href="#section3.01">3.01</a></td><td align="left" valign="top"><a href="#section3.01">LCA drug comparators may be adopted from other jurisdictions</a></td></tr><tr><td align="left"> </td><td align="right" valign="top" width="auto"><a href="#section3.1">3.1</a></td><td align="left" valign="top"><a href="#section3.1">Repealed</a></td></tr><tr><td align="left"> </td><td align="right" valign="top" width="auto"><a href="#section4">4</a></td><td align="left" valign="top"><a href="#section4">Low cost alternative categories established on or after April 1, 2013</a></td></tr><tr><td align="left"> </td><td align="right" valign="top" width="auto"><a href="#section5">5</a></td><td align="left" valign="top"><a href="#section5">Low cost alternative categories established before April 1, 2013</a></td></tr><tr><td align="left"> </td><td align="right" valign="top" width="auto"><a href="#section6">6</a></td><td align="left" valign="top"><a href="#section6">Reference drug program</a></td></tr><tr><td align="left"> </td><td align="right" valign="top" width="auto"><a href="#section7">7</a></td><td align="left" valign="top"><a href="#section7">High cost drugs</a></td></tr></tr><tr><td align="left"> </td><td align="left" class="division" colspan="2" valign="top"><a href="#division_d2e977">Division 2 — Maximum Payment Amounts</a></td><tr><td align="left"> </td><td align="right" valign="top" width="auto"><a href="#section8">8</a></td><td align="left" valign="top"><a href="#section8">Minister must not pay more than maximum amount</a></td></tr><tr><td align="left"> </td><td align="right" valign="top" width="auto"><a href="#section9">9</a></td><td align="left" valign="top"><a href="#section9">Maximum payment for non-reference drugs</a></td></tr><tr><td align="left"> </td><td align="right" valign="top" width="auto"><a href="#section10">10</a></td><td align="left" valign="top"><a href="#section10">Maximum payment for high cost drugs</a></td></tr><tr><td align="left"> </td><td align="right" valign="top" width="auto"><a href="#section11">11</a></td><td align="left" valign="top"><a href="#section11">Prices for other drugs</a></td></tr><tr><td align="left"> </td><td align="right" valign="top" width="auto"><a href="#section12">12</a></td><td align="left" valign="top"><a href="#section12">Price if unanticipated drug shortage</a></td></tr><tr><td align="left"> </td><td align="right" valign="top" width="auto"><a href="#section13">13</a></td><td align="left" valign="top"><a href="#section13">Price if inter-jurisdictional agreement applies</a></td></tr></tr><tr><td align="left" class="part" colspan="3" valign="top"><a href="#part3">Part 3 — Listing Drugs</a></td></tr><tr><td align="left"> </td><td align="right" valign="top" width="auto"><a href="#section14">14</a></td><td align="left" valign="top"><a href="#section14">Designation of provisional drugs</a></td></tr><tr><td align="left"> </td><td align="right" valign="top" width="auto"><a href="#section15">15</a></td><td align="left" valign="top"><a href="#section15">Minister not to list certain generic drugs</a></td></tr><tr><td align="left"> </td><td align="right" valign="top" width="auto"><a href="#section16">16</a></td><td align="left" valign="top"><a href="#section16">Temporary listing of drugs</a></td></tr><tr><td align="left" class="part" colspan="3" valign="top"><a href="#part4">Part 4</a></td></tr><tr><td align="left"> </td><td align="right" valign="top" width="auto"><a href="#section17">17</a></td><td align="left" valign="top"><a href="#section17">Repealed</a></td></tr><tr><td align="left" class="part" colspan="3" valign="top"><a href="#Schedule">Schedule</a></td></tr></table></div><p class="part" id="d2e40"><a name="part1"></a>Part 1 — Definitions and Application</p><div class="section"><a name="section1"></a><h4><a name="section1"></a>Definitions</h4><p id="d2e49" class="sec "><span class="secnum"><span class="secnumholder"><b>1</b>		  <a name="d2e57"></a>(1) </span></span>In this regulation:</p><p id="d2e66" class="def"><span id="Act" class="normal-bold-style">"Act"</span> means the <a href="/civix/document/id/complete/statreg/12022_01"><em>Pharmaceutical Services Act</em></a>;</p><p id="d2e78" class="def"><span id="brand+drug" class="normal-bold-style">"brand drug"</span> means a drug</p><p class="para"><a name="d2e88"></a><span class="num"><span class="holder">(a)</span></span> for which the first notice of compliance has been issued under section C.08.004 or C.08.004.01 of the Food and Drug Regulations (Canada), C.R.C., c. 870, in respect of all 3 of the following:</p><p class="subpara"><a name="d2e97"></a><span class="num"><span class="holder">(i) </span></span> a particular active ingredient or combination of particular active ingredients;</p><p class="subpara"><a name="d2e106"></a><span class="num"><span class="holder">(ii) </span></span> strength;</p><p class="subpara"><a name="d2e115"></a><span class="num"><span class="holder">(iii) </span></span> dosage form, and</p><p class="para"><a name="d2e124"></a><span class="num"><span class="holder">(b)</span></span> that, before the issuance of any subsequent notice of compliance for another drug having the same active ingredient or combination of active ingredients, is or was marketed in Canada by</p><p class="subpara"><a name="d2e133"></a><span class="num"><span class="holder">(i) </span></span> the drug's innovator, or</p><p class="subpara"><a name="d2e143"></a><span class="num"><span class="holder">(ii) </span></span> a person acting under a licence granted by the drug's innovator;</p><p id="d2e152" class="def"><span id="generic+drug" class="normal-bold-style">"generic drug"</span> means a drug having the same active ingredient or combination of active ingredients as a brand drug;</p><p id="d1e169" class="def"><span id="generic+drug+inclusion+or+exclusion" class="normal-bold-style">"generic drug inclusion or exclusion"</span> means the inclusion of at least one additional generic drug in, or the exclusion of at least one generic drug from, an LCA category;</p><p id="d2e161" class="def"><span id="high+cost+drug" class="normal-bold-style">"high cost drug"</span> means a high cost drug designated under section 7 (1) <em>[high cost drugs]</em>;</p><p id="d2e173" class="def"><span id="LCA+category" class="normal-bold-style">"LCA category"</span> means a category of drugs established under section 3 (1) (a) <em>[LCA program]</em>;</p><p id="d2e185" class="def"><span id="LCA+drug+comparator" class="normal-bold-style">"LCA drug comparator"</span> means the drug designated under section 3 (1) (c) as the LCA drug comparator for an LCA category;</p><p id="d2e194" class="def"><span id="LCA+program" class="normal-bold-style">"LCA program"</span> means the low cost alternative program under section 3;</p><p id="d2e204" class="def"><span id="manufacturer's+list+price" class="normal-bold-style">"manufacturer's list price"</span> means the following:</p><p class="para"><a name="d1e239"></a><span class="num"><span class="holder">(a)</span></span> in the case of an LCA category having an LCA drug comparator adopted from another jurisdiction under section 3.01 (1) (a) <em>[LCA drug comparators may be adopted from other jurisdictions]</em>, the manufacturer's list price per unit of the adopted drug in that jurisdiction;</p><p class="para"><a name="d1e251"></a><span class="num"><span class="holder">(b)</span></span> in any other case, the price per unit of a drug, as provided by a manufacturer to the minister in the manner and at the time required by the minister;</p><p id="d2e213" class="def"><span id="maximum+accepted+list+price" class="normal-bold-style">"maximum accepted list price"</span> means the maximum accepted list price as determined by the minister under section 3 (3);</p><p id="d2e222" class="def"><span id="non-reference+drug" class="normal-bold-style">"non-reference drug"</span> means a drug, within a reference drug category, that has not been designated as a reference drug;</p><p id="d2e231" class="def"><span id="oral+solid" class="normal-bold-style">"oral solid"</span> means a drug that</p><p class="para"><a name="d2e240"></a><span class="num"><span class="holder">(a)</span></span> is available in a solid form, including as a gel capsule, chewable tablet or wafer, and</p><p class="para"><a name="d2e249"></a><span class="num"><span class="holder">(b)</span></span> is intended to be taken orally;</p><p id="d2e259" class="def"><span id="provisional+drug" class="normal-bold-style">"provisional drug"</span> means a drug designated under section 14 (1) <em>[designation of provisional drugs]</em> as a provisional drug;</p><p id="d2e271" class="def"><span id="reference+drug" class="normal-bold-style">"reference drug"</span> means a drug, within a reference drug category, designated under section 6 (2) (b) <em>[reference drug program]</em> as a reference drug;</p><p id="d2e283" class="def"><span id="reference+drug+category" class="normal-bold-style">"reference drug category"</span> means a category of drugs listed in section 6 (1);</p><p id="d2e292" class="def"><span id="reference+drug+comparator" class="normal-bold-style">"reference drug comparator"</span> means the drug designated under section 6 (2) (c) as the reference drug comparator for a reference drug category.</p><p class="sub"><a name="d2e301"></a><span class="num"><span class="holder">(2) </span></span>Despite subsection (1), the minister may do one or both of the following for the purposes of the LCA program:</p><p class="para"><a name="d2e310"></a><span class="num"><span class="holder">(a)</span></span> deem a generic drug to be a brand drug;</p><p class="para"><a name="d2e320"></a><span class="num"><span class="holder">(b)</span></span> deem a brand drug to be a generic drug.</p><p class="hnote">[am. B.C. Regs. 266/2016, Sch. 2, s. 1; 22/2019, s. 1.]</p></div><div class="section"><a name="section2"></a><h4><a name="section2"></a>Application</h4><p id="d2e330" class="sec nosubsecnum"><span class="secnum"><span class="secnumholder"><b>2</b>		  </span></span>This regulation applies only to drugs, except insulin, that are benefits under the Act.</p></div><p class="part" id="d2e342"><a name="part2"></a>Part 2 — Maximum Amounts Payable by Minister</p><p class="division" id="d2e351"><a name="division_d2e351"></a>Division 1 — Drug Programs</p><div class="section"><a name="section3"></a><h4><a name="section3"></a>Low cost alternative program</h4><p id="d2e364" class="sec "><span class="secnum"><span class="secnumholder"><b>3</b>
		  <a name="d2e372"></a>(1) </span></span>For the purposes of the low cost alternative program, the minister</p><p class="para"><a name="d2e381"></a><span class="num"><span class="holder">(a)</span></span> may establish LCA categories consisting of drugs that have the same active ingredient or combination of active ingredients, and the same strength,</p><p class="para"><a name="d2e390"></a><span class="num"><span class="holder">(b)</span></span> may, for each category, determine which drugs are included, and</p><p class="para"><a name="d2e400"></a><span class="num"><span class="holder">(c)</span></span> may, for each category established on or after April 1, 2013, designate one drug as the LCA drug comparator.</p><p class="sub"><a name="d2e409"></a><span class="num"><span class="holder">(2) </span></span>If the minister designates an LCA drug comparator, the minister must designate the LCA drug comparator as follows:</p><p class="para"><a name="d2e418"></a><span class="num"><span class="holder">(a)</span></span> if there is a single brand drug in an LCA category, that brand drug;</p><p class="para"><a name="d2e427"></a><span class="num"><span class="holder">(b)</span></span> if there is more than one brand drug in an LCA category, the brand drug that, in the opinion of the minister is the most cost-effective of the brand drugs in the category;</p><p class="para"><a name="d2e436"></a><span class="num"><span class="holder">(c)</span></span> if there are no brand drugs in an LCA category, the LCA drug comparator of another LCA category having drugs with the same active ingredient or combination of active ingredients, but a different strength, as the first LCA category;</p><p class="para"><a name="d1e509"></a><span class="num"><span class="holder">(d)</span></span> despite paragraphs (a) to (c), if section 3.01 <em>[LCA drug comparators may be adopted from other jurisdictions]</em> applies, as described in that section.</p><p class="sub"><a name="d2e445"></a><span class="num"><span class="holder">(3) </span></span>The minister must determine the maximum accepted list price for the drugs in each LCA category in accordance with the following, as applicable:</p><p class="para"><a name="d2e455"></a><span class="num"><span class="holder">(a)</span></span> section 4 <em>[LCA categories established on or after April 1, 2013]</em>;</p><p class="para"><a name="d2e467"></a><span class="num"><span class="holder">(b)</span></span> section 5 <em>[LCA categories established before April 1, 2013]</em>.</p><p class="sub"><a name="d2e479"></a><span class="num"><span class="holder">(4) </span></span>The minister may change or cancel a determination or designation made under this section, including cancelling the establishment of an LCA category.</p><p class="sub"><a name="d2e488"></a><span class="num"><span class="holder">(5) </span></span>A change or cancellation under subsection (4) may be made at any time without notice to anyone or an opportunity to be heard.</p><p class="sub"><a name="d2e497"></a><span class="num"><span class="holder">(6) </span></span>The minister must publish on the website of the ministry of the minister all of the following:</p><p class="para"><a name="d2e506"></a><span class="num"><span class="holder">(a)</span></span> a list of all LCA categories;</p><p class="para"><a name="d2e516"></a><span class="num"><span class="holder">(b)</span></span> for each LCA category, the maximum amount the minister may pay under the Act for a drug within the LCA category.</p><p class="hnote">[am. B.C. Reg. 22/2019, s. 2.]</p></div><div class="section"><a name="section3.01"></a><h4><a name="section3.01"></a>LCA drug comparators may be adopted from other jurisdictions</h4><p id="d1e614" class="sec "><span class="secnum"><span class="secnumholder"><b>3.01</b>
		  <a name="d1e622"></a>(1) </span></span>If, under subsection (2) of this section, this subsection applies to an LCA category established under section 3 (1) (a), the minister may designate an LCA drug comparator for the category as follows:</p><p class="para"><a name="d1e630"></a><span class="num"><span class="holder">(a)</span></span> by adopting as the LCA drug comparator a brand drug that is used by another jurisdiction of Canada as the reference drug to determine prices for a category of drugs, established in that jurisdiction, that is similar to the LCA category;</p><p class="para"><a name="d1e639"></a><span class="num"><span class="holder">(b)</span></span> if the brand drug referred to in paragraph (a) of this subsection is not on a formulary of British Columbia, or for any other reason, in accordance with section 3 (2) (a) to (c), as applicable.</p><p class="sub"><a name="d1e649"></a><span class="num"><span class="holder">(2) </span></span>Subsection (1) applies to an LCA category as follows:</p><p class="para"><a name="d1e657"></a><span class="num"><span class="holder">(a)</span></span> if the LCA category is established before April 1, 2014 and has no generic drug inclusions or exclusions before April 1, 2019, subsection (1) applies as of the date of the first generic drug inclusion or exclusion that occurs on or after April 1, 2019;</p><p class="para"><a name="d1e666"></a><span class="num"><span class="holder">(b)</span></span> if the LCA category is established</p><p class="subpara"><a name="d1e674"></a><span class="num"><span class="holder">(i) </span></span> before April 1, 2014 but has a generic drug inclusion or exclusion on or after April 1, 2014 but before April 1, 2019, or</p><p class="subpara"><a name="d1e683"></a><span class="num"><span class="holder">(ii) </span></span> on or after April 1, 2014 but before April 1, 2019,</p><p class="para sandwich">subsection (1) applies as of the date of the first generic drug inclusion or exclusion that occurs on or after April 1, 2019, and causes the LCA category to move into a different tier as described in subsection (3);</p><p class="para"><a name="d1e696"></a><span class="num"><span class="holder">(c)</span></span> if the LCA category is established on or after April 1, 2019, subsection (1) applies as of the date that the LCA category is established.</p><p class="sub"><a name="d1e706"></a><span class="num"><span class="holder">(3) </span></span>For the purposes of subsection (2) (b), an LCA category moves into a different tier if any of the following occurs:</p><p class="para"><a name="d1e714"></a><span class="num"><span class="holder">(a)</span></span> a category having only one generic drug has at least one more generic drug included in the category;</p><p class="para"><a name="d1e723"></a><span class="num"><span class="holder">(b)</span></span> a category having only 2 generic drugs has</p><p class="subpara"><a name="d1e731"></a><span class="num"><span class="holder">(i) </span></span> one generic drug excluded from the category such that only one generic drug remains in that category, or</p><p class="subpara"><a name="d1e740"></a><span class="num"><span class="holder">(ii) </span></span> at least one more generic drug included in the category;</p><p class="para"><a name="d1e750"></a><span class="num"><span class="holder">(c)</span></span> a category having 3 or more generic drugs has generic drugs excluded from the category such that only one or 2 generic drugs remain in that category.</p><p class="hnote">[en. B.C. Reg. 22/2019, s. 3.]</p></div><div class="section"><a name="section3.1"></a><h4><a name="section3.1"></a>Repealed</h4><p id="d0e579" class="sec nosubsecnum"><span class="secnum"><span class="secnumholder"><b>3.1</b>
		  </span></span>Repealed. [B.C. Reg. 22/2019, s. 4.]</p></div><div class="section"><a name="section4"></a><h4><a name="section4"></a>Low cost alternative categories established on or after April 1, 2013</h4><p id="d2e526" class="sec "><span class="secnum"><span class="secnumholder"><b>4</b>
		  <a name="d2e534"></a>(1) </span></span>This section applies to LCA categories established on or after April 1, 2013.</p><p class="sub"><a name="d2e543"></a><span class="num"><span class="holder">(2) </span></span>Except as set out in subsections (3) and (4), the maximum accepted list price for drugs in an LCA category that meets both of the following criteria is 25% of the manufacturer's list price for the LCA drug comparator for the LCA category, as of the date on which a generic drug is first included in or excluded from the category after April 1, 2019:</p><p class="para"><a name="d2e552"></a><span class="num"><span class="holder">(a)</span></span> the LCA category consists of drugs available as oral solids only;</p><p class="para"><a name="d2e562"></a><span class="num"><span class="holder">(b)</span></span> the LCA category was established</p><p class="subpara"><a name="d1e820"></a><span class="num"><span class="holder">(i) </span></span> on or after April 1, 2019, or</p><p class="subpara"><a name="d1e829"></a><span class="num"><span class="holder">(ii) </span></span> before April 1, 2019, but has a generic drug inclusion or exclusion on or after April 1, 2019.</p><p class="sub"><a name="d1e840"></a><span class="num"><span class="holder">(2.1) </span></span>Except as set out in subsections (3) and (4), the maximum accepted list price for drugs in an LCA category is the following percentage of the manufacturer's list price for the LCA drug comparator for that LCA category, as of the date on which a generic drug is first assigned to that LCA category:</p><p class="para"><a name="d1e848"></a><span class="num"><span class="holder">(a)</span></span> 20%, if the LCA category consists of drugs available as oral solids only but subsection (2) does not apply;</p><p class="para"><a name="d1e857"></a><span class="num"><span class="holder">(b)</span></span> 35%, in any other case.</p><p class="sub"><a name="d2e571"></a><span class="num"><span class="holder">(3) </span></span>If the manufacturer's list price of an LCA drug comparator decreased by more than 20% within 2 years before a generic drug is first assigned to the LCA category, the date for the purposes of subsection (2) is the date that is 2 years before a generic drug is first assigned to that LCA category.</p><p class="sub"><a name="d2e580"></a><span class="num"><span class="holder">(4) </span></span>If section 3 (2) (c) <em>[LCA program]</em> applies, the maximum accepted list price for drugs in the LCA category having no brand drugs is proportional, depending on their strength, to the maximum accepted list price that applies to the LCA category to which the designated LCA drug comparator belongs.</p><p class="hnote">[am. B.C. Regs. 344/2012, s. (d); 22/2019, s. 5.]</p></div><div class="section"><a name="section5"></a><h4><a name="section5"></a>Low cost alternative categories established before April 1, 2013</h4><p id="d2e593" class="sec "><span class="secnum"><span class="secnumholder"><b>5</b>
		  <a name="d2e601"></a>(1) </span></span>This section applies to LCA categories established before April 1, 2013.</p><p class="sub"><a name="d2e610"></a><span class="num"><span class="holder">(2) </span></span>Except as set out in subsection (3), the maximum accepted list price for drugs in an LCA category listed in Column 1 of the Schedule is as follows:</p><p class="para"><a name="d2e619"></a><span class="num"><span class="holder">(a)</span></span> 25% of the base price set out in Column 2 of the Schedule opposite the LCA category if the LCA category</p><p class="subpara"><a name="d1e932"></a><span class="num"><span class="holder">(i) </span></span> consists of drugs available as oral solids only, and</p><p class="subpara"><a name="d1e941"></a><span class="num"><span class="holder">(ii) </span></span> has a generic drug inclusion or exclusion on or after April 1, 2019;</p><p class="para"><a name="d2e629"></a><span class="num"><span class="holder">(b)</span></span> 20% of the base price set out in Column 2 of the Schedule opposite the LCA category if the LCA category consists of drugs available as oral solids only but paragraph (a) (ii) does not apply;</p><p class="para"><a name="d1e960"></a><span class="num"><span class="holder">(c)</span></span> 35% of the base price set out in Column 2 of the Schedule opposite that LCA category in any other case.</p><p class="sub"><a name="d2e638"></a><span class="num"><span class="holder">(3) </span></span>If a drug in an LCA category had, as of July 1, 2010, a lower manufacturer's list price than the maximum accepted list price calculated under subsection (2), the maximum accepted list price for drugs in the LCA category is the manufacturer's list price, as of July 1, 2010, of the lower priced drug.</p><p class="sub"><a name="d2e647"></a><span class="num"><span class="holder">(4) </span></span>The minister may deem, at any time, an LCA category established before April 1, 2013, to have been established on or after April 1, 2013, in which case,</p><p class="para"><a name="d2e656"></a><span class="num"><span class="holder">(a)</span></span> the maximum accepted list price for drugs in the LCA category is to be determined in accordance with section 4 <em>[LCA categories established on or after April 1, 2013]</em>, and</p><p class="para"><a name="d2e668"></a><span class="num"><span class="holder">(b)</span></span> for the purposes of section 4 (2.1), the date on which a generic drug is first assigned to the LCA category is deemed to be the date on which the minister deems the LCA category to have been established.</p><p class="hnote">[am. B.C. Regs. 344/2012, s. (d); 22/2019, s. 6.]</p></div><div class="section"><a name="section6"></a><h4><a name="section6"></a>Reference drug program</h4><p id="d2e678" class="sec "><span class="secnum"><span class="secnumholder"><b>6</b>
		  <a name="d2e686"></a>(1) </span></span>The following are reference drug categories for the purposes of the reference drug program:</p><p class="para"><a name="d2e695"></a><span class="num"><span class="holder">(a)</span></span> angiotensin converting enzyme inhibitors;</p><p class="para"><a name="d0e759"></a><span class="num"><span class="holder">(b)</span></span> angiotensin receptor blockers;</p><p class="para"><a name="d2e704"></a><span class="num"><span class="holder">(c)</span></span> dihydropyridine calcium channel blockers;</p><p class="para"><a name="d2e714"></a><span class="num"><span class="holder">(d)</span></span> histamine-2 receptor antagonists;</p><p class="para"><a name="d0e786"></a><span class="num"><span class="holder">(e)</span></span> hydroxyl-3-methylglutaryl-coenzyme A reductase inhibitors;</p><p class="para"><a name="d2e732"></a><span class="num"><span class="holder">(f)</span></span> non-steroidal anti-inflammatory drugs;</p><p class="para"><a name="d2e723"></a><span class="num"><span class="holder">(g)</span></span> oral nitrates;</p><p class="para"><a name="d0e813"></a><span class="num"><span class="holder">(h)</span></span> proton pump inhibitors.</p><p class="sub"><a name="d2e741"></a><span class="num"><span class="holder">(2) </span></span>The minister may, for each category,</p><p class="para"><a name="d2e750"></a><span class="num"><span class="holder">(a)</span></span> determine which drugs are included,</p><p class="para"><a name="d2e759"></a><span class="num"><span class="holder">(b)</span></span> designate one or more drugs as reference drugs, and</p><p class="para"><a name="d2e769"></a><span class="num"><span class="holder">(c)</span></span> designate one drug as the reference drug comparator.</p><p class="sub"><a name="d2e778"></a><span class="num"><span class="holder">(3) </span></span>A drug may be designated as a reference drug if the minister is of the opinion that the drug is at least as clinically efficacious or cost-effective as other drugs in the reference drug category.</p><p class="sub"><a name="d2e787"></a><span class="num"><span class="holder">(4) </span></span>The minister may designate any of the following as the reference drug comparator:</p><p class="para"><a name="d2e796"></a><span class="num"><span class="holder">(a)</span></span> the reference drug that, in the opinion of the minister, is the most cost-effective of the reference drugs in the reference drug category;</p><p class="para"><a name="d2e805"></a><span class="num"><span class="holder">(b)</span></span> the drug that was designated before April 1, 2013, as the reference drug comparator for the reference drug category;</p><p class="para"><a name="d2e814"></a><span class="num"><span class="holder">(c)</span></span> the drug, in the reference drug category, that, in the opinion of the minister, will best serve the public interest if designated as the reference drug comparator for the reference drug category.</p><p class="sub"><a name="d2e824"></a><span class="num"><span class="holder">(5) </span></span>The minister must determine the daily therapeutic dose of the reference drug comparator, the daily therapeutic dose being</p><p class="para"><a name="d2e833"></a><span class="num"><span class="holder">(a)</span></span> the typical dose that is prescribed, and</p><p class="para"><a name="d2e842"></a><span class="num"><span class="holder">(b)</span></span> the number of doses that a beneficiary would typically receive each day.</p><p class="sub"><a name="d2e851"></a><span class="num"><span class="holder">(6) </span></span>The minister may change or cancel a determination or designation made under this section.</p><p class="sub"><a name="d2e860"></a><span class="num"><span class="holder">(7) </span></span>A change or cancellation under subsection (6) may be made at any time without notice to anyone or an opportunity to be heard.</p><p class="sub"><a name="d2e869"></a><span class="num"><span class="holder">(8) </span></span>The minister must publish on the website of the ministry of the minister a list of all of the following for each reference drug category:</p><p class="para"><a name="d2e879"></a><span class="num"><span class="holder">(a)</span></span> the drugs that are included;</p><p class="para"><a name="d2e888"></a><span class="num"><span class="holder">(b)</span></span> the drugs that have been designated as reference drugs;</p><p class="para"><a name="d2e897"></a><span class="num"><span class="holder">(c)</span></span> the drug that has been designated as the reference drug comparator and the applicable daily therapeutic dose;</p><p class="para"><a name="d2e906"></a><span class="num"><span class="holder">(d)</span></span> the maximum daily amount the minister may pay under the Act for a non-reference drug, as determined under section 9 <em>[maximum payment for non-reference drugs]</em>.</p><p class="hnote">[am. B.C. Reg. 255/2015.]</p></div><div class="section"><a name="section7"></a><h4><a name="section7"></a>High cost drugs</h4><p id="d2e919" class="sec "><span class="secnum"><span class="secnumholder"><b>7</b>
		  <a name="d2e927"></a>(1) </span></span>The minister may designate a drug as a high cost drug if the minister determines that the maximum daily amount the minister may pay for the drug when averaged over a one-year period is equal to or greater than $40, having regard to the following factors:</p><p class="para"><a name="d2e936"></a><span class="num"><span class="holder">(a)</span></span> the maximum amount the minister would otherwise pay, as determined under section 11 <em>[prices for other drugs]</em>, if the drug were not designated as a high cost drug;</p><p class="para"><a name="d2e948"></a><span class="num"><span class="holder">(b)</span></span> the typical dose that is prescribed;</p><p class="para"><a name="d2e958"></a><span class="num"><span class="holder">(c)</span></span> the number of doses that a beneficiary would typically receive each year.</p><p class="sub"><a name="d2e967"></a><span class="num"><span class="holder">(2) </span></span>The minister must publish on the website of the ministry of the minister a list of all high cost drugs.</p></div><p class="division" id="d2e977"><a name="division_d2e977"></a>Division 2 — Maximum Payment Amounts</p><div class="section"><a name="section8"></a><h4><a name="section8"></a>Minister must not pay more than maximum amount</h4><p id="d2e990" class="sec nosubsecnum"><span class="secnum"><span class="secnumholder"><b>8</b>
		  </span></span>The minister must not make a payment under the Act for a drug in an amount that is greater than provided for in this Division.</p></div><div class="section"><a name="section9"></a><h4><a name="section9"></a>Maximum payment for non-reference drugs</h4><p id="d2e1002" class="sec "><span class="secnum"><span class="secnumholder"><b>9</b>
		  <a name="d2e1010"></a>(1) </span></span>The maximum amount the minister may pay for a non-reference drug that is not subject to the LCA program is the lesser of</p><p class="para"><a name="d2e1019"></a><span class="num"><span class="holder">(a)</span></span> the sum of the manufacturer's list price for the drug and 8% of that price, and</p><p class="para"><a name="d2e1028"></a><span class="num"><span class="holder">(b)</span></span> the maximum daily amount the minister may pay for the reference drug comparator for the reference drug category to which the non-reference drug belongs, as if the reference drug comparator were being dispensed at the daily therapeutic dose determined under section 6 (5) <em>[reference drug program]</em>.</p><p class="sub"><a name="d2e1041"></a><span class="num"><span class="holder">(2) </span></span>The maximum amount the minister may pay for a non-reference drug that is subject to the LCA program is the lesser of</p><p class="para"><a name="d2e1050"></a><span class="num"><span class="holder">(a)</span></span> the amount determined under subsection (1), as if the non-reference drug were not subject to the LCA program, and</p><p class="para"><a name="d2e1059"></a><span class="num"><span class="holder">(b)</span></span> either,</p><p class="subpara"><a name="d2e1068"></a><span class="num"><span class="holder">(i) </span></span> if there are no provisional drugs in the LCA category to which the non-reference drug belongs, the sum of the maximum accepted list price for the LCA category to which the drug belongs and 8% of that price, or</p><p class="subpara"><a name="d2e1077"></a><span class="num"><span class="holder">(ii) </span></span> if there are provisional drugs in the LCA category to which the non-reference drug belongs, the maximum amount the minister may pay for a drug under section 11 (4) <em>[prices for other drugs]</em>.</p></div><div class="section"><a name="section10"></a><h4><a name="section10"></a>Maximum payment for high cost drugs</h4><p id="d2e1090" class="sec "><span class="secnum"><span class="secnumholder"><b>10</b>
		  <a name="d2e1098"></a>(1) </span></span>The maximum amount the minister may pay for a high cost drug that is not subject to the LCA program is the sum of the manufacturer's list price for the drug and 5% of that price.</p><p class="sub"><a name="d2e1107"></a><span class="num"><span class="holder">(2) </span></span>The maximum amount the minister may pay for a high cost drug that is subject to the LCA program is the lesser of</p><p class="para"><a name="d2e1116"></a><span class="num"><span class="holder">(a)</span></span> the amount determined under subsection (1), as if the high cost drug were not subject to the LCA program, and</p><p class="para"><a name="d2e1126"></a><span class="num"><span class="holder">(b)</span></span> the applicable amount from among the following:</p><p class="subpara"><a name="d2e1135"></a><span class="num"><span class="holder">(i) </span></span> if, in the LCA category to which the high cost drug belongs, there are only high cost drugs and none are provisional drugs, the sum of the maximum accepted list price for the LCA category to which the drug belongs and 5% of that price;</p><p class="subpara"><a name="d2e1144"></a><span class="num"><span class="holder">(ii) </span></span> if, in the LCA category to which the high cost drug belongs, there are one or more drugs that are not high cost drugs but there are no provisional drugs, the sum of the maximum accepted list price for the LCA category to which the drug belongs and 8% of that price;</p><p class="subpara"><a name="d2e1153"></a><span class="num"><span class="holder">(iii) </span></span> if, in the LCA category to which the high cost drug belongs, there are one or more provisional drugs, the maximum amount the minister may pay for a drug under section 11 (4) <em>[prices for other drugs]</em>.</p></div><div class="section"><a name="section11"></a><h4><a name="section11"></a>Prices for other drugs</h4><p id="d2e1166" class="sec "><span class="secnum"><span class="secnumholder"><b>11</b>
		  <a name="d2e1174"></a>(1) </span></span>This section applies to drugs other than non-reference drugs and high cost drugs.</p><p class="sub"><a name="d2e1183"></a><span class="num"><span class="holder">(2) </span></span>The maximum amount the minister may pay for a drug that is not subject to the LCA program is the sum of the manufacturer's list price for the drug and 8% of that price.</p><p class="sub"><a name="d2e1192"></a><span class="num"><span class="holder">(3) </span></span>The maximum amount the minister may pay for a drug that is subject to the LCA program and is in an LCA category having no provisional drugs is the lesser of</p><p class="para"><a name="d2e1202"></a><span class="num"><span class="holder">(a)</span></span> the sum of the maximum accepted list price for the LCA category to which the drug belongs and 8% of that price, and</p><p class="para"><a name="d2e1211"></a><span class="num"><span class="holder">(b)</span></span> the sum of the manufacturer's list price for the drug and 8% of that price.</p><p class="sub"><a name="d2e1220"></a><span class="num"><span class="holder">(4) </span></span>The maximum amount the minister may pay for a drug that is subject to the LCA program and is in an LCA category having one or more provisional drugs is the sum of the manufacturer's list price for the highest-priced provisional drug and</p><p class="para"><a name="d2e1229"></a><span class="num"><span class="holder">(a)</span></span> 8% of that price if the provisional drug is not a high cost drug, or</p><p class="para"><a name="d2e1238"></a><span class="num"><span class="holder">(b)</span></span> 5% of that price if the provisional drug is a high cost drug.</p><p class="sub"><a name="d2e1247"></a><span class="num"><span class="holder">(5) </span></span>Despite subsections (2) to (4) of this section, if an agreement under section 20 (2) <em>[price regulation]</em> of the Act includes a term respecting the price of a drug, the maximum amount the minister may pay for the drug is the agreed price.</p></div><div class="section"><a name="section12"></a><h4><a name="section12"></a>Price if unanticipated drug shortage</h4><p id="d2e1260" class="sec "><span class="secnum"><span class="secnumholder"><b>12</b>
		  <a name="d2e1268"></a>(1) </span></span>This section applies to</p><p class="para"><a name="d2e1277"></a><span class="num"><span class="holder">(a)</span></span> a brand drug within an LCA category having an insufficient supply of drugs as described in section 16 (1) <em>[temporary listing of drugs]</em>, and</p><p class="para"><a name="d2e1289"></a><span class="num"><span class="holder">(b)</span></span> a drug that is temporarily listed under section 16 (2).</p><p class="sub"><a name="d2e1299"></a><span class="num"><span class="holder">(2) </span></span>If section 16 (1) applies, despite sections 9 <em>[maximum payment for non-reference drugs]</em> to 11 <em>[prices for other drugs]</em>, the maximum amount the minister may pay for a drug referred to in subsection (1) of this section during the period of unanticipated shortage is as follows:</p><p class="para"><a name="d2e1314"></a><span class="num"><span class="holder">(a)</span></span> if the drug is a non-reference drug, the lesser of</p><p class="subpara"><a name="d2e1323"></a><span class="num"><span class="holder">(i) </span></span> the sum of the manufacturer's list price for the drug and 8% of that price, and</p><p class="subpara"><a name="d2e1332"></a><span class="num"><span class="holder">(ii) </span></span> the maximum daily amount the minister may pay for the reference drug comparator for the reference drug category to which the non-reference drug belongs, as if the reference drug comparator were being dispensed at the daily therapeutic dose determined under section 6 (5) <em>[reference drug program]</em>;</p><p class="para"><a name="d2e1344"></a><span class="num"><span class="holder">(b)</span></span> if the drug is a high cost drug, the sum of the manufacturer's list price for the drug and 5% of that price;</p><p class="para"><a name="d2e1353"></a><span class="num"><span class="holder">(c)</span></span> in any other case, the sum of the manufacturer's list price for the drug and 8% of that price.</p></div><div class="section"><a name="section13"></a><h4><a name="section13"></a>Price if inter-jurisdictional agreement applies</h4><p id="d2e1363" class="sec nosubsecnum"><span class="secnum"><span class="secnumholder"><b>13</b>
		  </span></span>If the government of British Columbia is a party, with the government of one or more other jurisdictions, to an agreement, a memorandum of understanding or another similar arrangement that is designed to provide for a supply of drugs at a price that is lower than the maximum amount the minister would otherwise pay under this Division,</p><p class="para"><a name="d2e1374"></a><span class="num"><span class="holder">(a)</span></span> sections 9 <em>[maximum payment for non-reference drugs]</em> to 12 <em>[price if unanticipated drug shortage]</em> do not apply, and</p><p class="para"><a name="d2e1389"></a><span class="num"><span class="holder">(b)</span></span> the maximum amount the minister may pay for a drug affected by the agreement, memorandum of understanding or arrangement is the amount resulting from the implementation of the agreement, memorandum of understanding or arrangement.</p></div><p class="part" id="d2e1400"><a name="part3"></a>Part 3 — Listing Drugs</p><div class="section"><a name="section14"></a><h4><a name="section14"></a>Designation of provisional drugs</h4><p id="d2e1409" class="sec "><span class="secnum"><span class="secnumholder"><b>14</b>
		  <a name="d2e1417"></a>(1) </span></span>The minister may designate a generic drug as a provisional drug if any of the following circumstances apply:</p><p class="para"><a name="d2e1426"></a><span class="num"><span class="holder">(a)</span></span> the minister is of the opinion that</p><p class="subpara"><a name="d2e1435"></a><span class="num"><span class="holder">(i) </span></span> there will be an insufficient supply of drugs within an LCA category, and</p><p class="subpara"><a name="d2e1445"></a><span class="num"><span class="holder">(ii) </span></span> listing the drug on a formulary is necessary to ensure a sufficient supply of drugs within the LCA category to which the drug is or would be assigned;</p><p class="para"><a name="d2e1454"></a><span class="num"><span class="holder">(b)</span></span> the drug could otherwise not be listed on a formulary under section 15 (2) (a) <em>[minister not to list certain generic drugs]</em>, but an agreement under section 20 (2) <em>[price regulation]</em> of the Act includes a term respecting the price of the drug;</p><p class="para"><a name="d2e1469"></a><span class="num"><span class="holder">(c)</span></span> the minister is of the opinion that listing the drug on a formulary is in the public interest.</p><p class="sub"><a name="d0e1701"></a><span class="num"><span class="holder">(1.1) </span></span>A generic drug's designation as a provisional drug is cancelled as follows:</p><p class="para"><a name="d0e1709"></a><span class="num"><span class="holder">(a)</span></span> Repealed. [B.C. Reg. 22/2019, s. 7.]</p><p class="para"><a name="d0e1718"></a><span class="num"><span class="holder">(b)</span></span> if the circumstances referred to in subsection (1) (a), (b) and (c) no longer apply, the minister may, at any time, cancel a designation made under this section in respect of any generic drug.</p><p class="sub"><a name="d2e1478"></a><span class="num"><span class="holder">(2) </span></span>The minister may cancel a designation made under this section without notice to anyone or an opportunity to be heard.</p><p class="sub"><a name="d2e1487"></a><span class="num"><span class="holder">(3) </span></span>Repealed. [B.C. Reg. 22/2019, s. 7.]</p><p class="hnote">[am. B.C. Regs. 266/2016, Sch. 2, s. 3; 22/2019, s. 7.]</p></div><div class="section"><a name="section15"></a><h4><a name="section15"></a>Minister not to list certain generic drugs</h4><p id="d2e1500" class="sec "><span class="secnum"><span class="secnumholder"><b>15</b>
		  <a name="d2e1508"></a>(1) </span></span>This section applies to a generic drug that is or would be assigned to an LCA category, but does not apply to a generic drug that is</p><p class="para"><a name="d2e1517"></a><span class="num"><span class="holder">(a)</span></span> a provisional drug, or</p><p class="para"><a name="d2e1526"></a><span class="num"><span class="holder">(b)</span></span> the subject of a term of an agreement, a memorandum of understanding or another arrangement under section 13 <em>[price if inter-jurisdictional agreement applies]</em>.</p><p class="sub"><a name="d2e1539"></a><span class="num"><span class="holder">(2) </span></span>The minister must refuse to list on a formulary a drug described in subsection (1), or must cancel the listing on a formulary of a drug described in subsection (1), if either of the following circumstances applies:</p><p class="para"><a name="d2e1548"></a><span class="num"><span class="holder">(a)</span></span> the manufacturer's list price for the drug is higher than the maximum accepted list price for the LCA category to which the drug is or would be assigned;</p><p class="para"><a name="d2e1557"></a><span class="num"><span class="holder">(b)</span></span> the manufacturer of the drug fails to supply information satisfactory to the minister respecting the drug within the time required by the minister.</p><p class="sub"><a name="d2e1566"></a><span class="num"><span class="holder">(3) </span></span>Repealed. [B.C. Reg. 22/2019, s. 7.]</p><p class="hnote">[am. B.C. Regs. 266/2016, Sch. 2, s. 4; 22/2019, s. 7.]</p></div><div class="section"><a name="section16"></a><h4><a name="section16"></a>Temporary listing of drugs</h4><p id="d2e1579" class="sec "><span class="secnum"><span class="secnumholder"><b>16</b>
		  <a name="d2e1587"></a>(1) </span></span>This section applies if the minister</p><p class="para"><a name="d2e1596"></a><span class="num"><span class="holder">(a)</span></span> is of the opinion that there is, or there is about to be, an insufficient supply of drugs within an LCA category, and</p><p class="para"><a name="d2e1605"></a><span class="num"><span class="holder">(b)</span></span> could not reasonably have anticipated the insufficient supply.</p><p class="sub"><a name="d2e1615"></a><span class="num"><span class="holder">(2) </span></span>Despite any other provision of this Part, the minister may list on a formulary, for the purpose of ensuring a sufficient supply of drugs within an LCA category, a drug that could not otherwise be listed.</p><p class="sub"><a name="d2e1624"></a><span class="num"><span class="holder">(3) </span></span>The minister must cancel the listing of the drug when the minister is of the opinion that the period of unanticipated shortage has ended.</p></div><p class="part" id="d2e1634"><a name="part4"></a>Part 4</p><div class="section"><a name="section17"></a><h4><a name="section17"></a>Repealed</h4><p id="d2e1643" class="sec nosubsecnum"><span class="secnum"><span class="secnumholder"><b>17</b>
		  </span></span>Repealed. [B.C. Reg. 266/2016, Sch. 2, s. 5.]</p></div><p align="center" class="bold"><a name="Schedule"></a>Schedule</p><p align="center">[am. B.C. Reg. 159/2013.]</p><p align="left"><em>The Schedule is exempt from publication and can be viewed at the following location:</em></p><p class="schIndent1">Pharmaceutical Services Division<br /> Ministry of Health<br /> 3rd floor, 1515 Blanshard Street<br /> Victoria, B.C. V8W 3C8</p><p class="schIndent1">Website: <a href="http://www.health.gov.bc.ca/pharmacare/publications.html">www.health.gov.bc.ca/pharmacare/publications.html</a></p><p class="provisionsnote">[Provisions relevant to the enactment of this regulation: <a href="/civix/document/id/complete/statreg/12022_01"><em>Pharmaceutical Services Act</em></a>, S.B.C. 2012, c. 22, ss. 62 (1) and (2) and 65 (3) and (5)]</p><p class="copyright">Copyright © King's Printer, Victoria, British							Columbia, Canada</p></div></body></html>
